UNLABELLED: Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. METHODS: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. RESULTS: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit(+) cells were found in the hCG + EPO group. CONCLUSION: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.
UNLABELLED: Erythropoietin (EPO) has the potential to improve ischemic tissue by mobilizing endothelial progenitor cells and enhancing neovascularization. We hypothesized that combining EPO with human chorionic gonadotrophin (hCG) would improve post-myocardial infarction (MI) effects synergistically. METHODS: After MI, five to seven animals were randomly assigned to each of the following treatments: control; hCG; EPO; hCG + EPO, and prolactin (PRL) + EPO. Follow-up echocardiograms were performed to assess cardiac structure and function. Apoptosis was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay and western blot analysis for apoptosis-related proteins, and cell proliferation by immunostaining for Ki67 and c-kit cells. RESULTS: The MI-mediated increased chamber systolic dimension (p < 0.05 in controls) was attenuated by hCG, EPO, and hCG + EPO (p < 0.05 vs. control) but not PRL + EPO. Similarly all treatment groups, except PRL + EPO, reduced MI-induced increases (p < 0.05 vs. control) in ejection fraction (EF). The functional improvement in the EPO-treated groups was accompanied by increased capillary density. Apoptosis was markedly reduced in all treated groups. Significantly more cardiac c-kit(+) cells were found in the hCG + EPO group. CONCLUSION: Our findings revealed that EPO, hCG, or their combination ameliorate cardiac remodeling post-MI. Whereas EPO stimulates neovascularization only and hCG + EPO stimulates c-kit+ cell proliferation. These data suggest that combining mobilizing and proliferative agents adds to the durability and sustainability of cytokine-based therapies for remodeling post-MI.
Authors: Chiara Melloni; Sunil V Rao; Thomas J Povsic; Laura Melton; Raymond J Kim; Rakhi Kilaru; Manesh R Patel; Mark Talan; Luigi Ferrucci; Dan L Longo; Edward G Lakatta; Samer S Najjar; Robert A Harrington Journal: Am Heart J Date: 2010-11 Impact factor: 4.749
Authors: A L Sirén; M Fratelli; M Brines; C Goemans; S Casagrande; P Lewczuk; S Keenan; C Gleiter; C Pasquali; A Capobianco; T Mennini; R Heumann; A Cerami; H Ehrenreich; P Ghezzi Journal: Proc Natl Acad Sci U S A Date: 2001-03-20 Impact factor: 11.205
Authors: G Bellone; C Rollino; S Borsa; I Ferrero; G Martina; A Carbone; K Mareschi; F Quarello; G Piccoli; G Emanuelli; L Matera Journal: Proc Soc Exp Biol Med Date: 2000-04
Authors: Rosemeire M Kanashiro-Takeuchi; Konstantinos Tziomalos; Lauro M Takeuchi; Adriana V Treuer; Guillaume Lamirault; Raul Dulce; Michael Hurtado; Yun Song; Norman L Block; Ferenc Rick; Anna Klukovits; Qinghua Hu; Jozsef L Varga; Andrew V Schally; Joshua M Hare Journal: Proc Natl Acad Sci U S A Date: 2010-01-21 Impact factor: 11.205
Authors: Hannelore Ehrenreich; Karin Weissenborn; Hilmar Prange; Dietmar Schneider; Christian Weimar; Katja Wartenberg; Peter D Schellinger; Matthias Bohn; Harald Becker; Martin Wegrzyn; Peter Jähnig; Manfred Herrmann; Michael Knauth; Mathias Bähr; Wolfgang Heide; Armin Wagner; Stefan Schwab; Heinz Reichmann; Günther Schwendemann; Reinhard Dengler; Andreas Kastrup; Claudia Bartels Journal: Stroke Date: 2009-10-15 Impact factor: 7.914
Authors: Ludmila Belayev; Larissa Khoutorova; Karen L Zhao; Allen W Davidoff; Alan F Moore; Steven C Cramer Journal: Brain Res Date: 2009-05-20 Impact factor: 3.252
Authors: Marek Malecki; Chelsea Sabo; Emily Putzer; Chris Stampe; Afsoon Foorohar; Carol Quach; Michael Beauchaine; Xenia Tombokan; Mark Anderson Journal: Mol Cell Ther Date: 2013-12-13